GILD - Gilead's Aggressive Push Beyond HIV Treatments - Plans To Increase Cancer-Focused CAR-T Treatment Production | Benzinga
Gilead Sciences Inc’s (NASDAQ:GILD) executive revealed the company’s plans to increase its production of cell therapy cancer treatments fourfold by 2026.
In an interview with Reuters, Cindy Perettie, the executive vice president of Gilead’s Kite cell therapy unit, said the advancements stem from significant enhancements in Gilead’s manufacturing processes.
Perettie noted that these improvements have increased the annual production of patient treatments from 6,000 to 10,000 within the past year.
Gilead’s focus on cell therapies, particularly its chimeric antigen receptor T-cell (CAR-T) treatments such as Yescarta and Tecartus, costing over $420,000, underscores its strategic shift towards ...